Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

Original reporting
Published Nov 5, 2026, 12:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adaptive Biotechnologies Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$ADPTBullishMed
01

Why it matters

Revenue growth and guidance lift indicate expanding market share, but cash burn and Medicare pricing remain risks.

02

Market read

Earnings and guidance update provide fresh data for traders; likely catalyst for short‑term price movement.

03

What to watch

Potential Medicare pricing pressure and pending MolDX bundle decision could temper upside.

Relevance 8/10Novelty 7/10Timing: post‑earnings release today

Background

Adaptive Biotechnologies provides clonoSEQ MRD testing for blood cancers; earnings reflect growing clinical and pharma demand.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Q3 earnings disclosed $83.9M revenue, GAAP net income $2.8M and raised full-year MRD revenue guidance to $276-$286M.

Expected impact

potential upside as market prices in higher MRD revenue outlook

Evidence & confidence

Guidance lift is a fresh, material update; investors typically reward higher revenue expectations.

Market effects

Positive for biotech firms with MRD testing platforms and related pharma partners.

U.S. biotech sector may see modest lift.

Limited to investors tracking precision‑medicine diagnostics.

Counterpoint

Guidance raise may be offset by higher operating expense expectations and lack of GAAP profit in Q4.

Key entities

  • Adaptive Biotechnologies

    Biotech firm offering clonoSEQ MRD testing.

  • MolDX

    Agency reviewing additional testing bundle request.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet